Main content

Evaluation of a Transdermal Drug Delivery System for Veterinary Patients

Show full item record

Title: Evaluation of a Transdermal Drug Delivery System for Veterinary Patients
Author: Kumagai, Miyuki
Department: Department of Biomedical Sciences
Program: Biomedical Sciences
Advisor: Johnson, Ronald
Abstract: Canine osteoarthritis (OA) is a progressive degenerative disease often leading to inflammation, pain and disuse of the affected joint. Meloxicam, commonly used to manage canine OA, is given as oral tablets or suspensions, or intravenous (IV) or subcutaneous (SC) injections. However, these routes are associated with decreased owner compliance and adverse drug reactions (ADRs) with chronic use. delivra™ uses the transdermal delivery route to transport meloxicam. Meloxicam compounded in delivra™ (TDM) was investigated to evaluate i) penetration of meloxicam into canine synovial fluid (SF) and plasma, ii) stability of TDM and iii) anti-inflammatory and analgesic properties of TDM. Results demonstrated that delivra™ was able to transport meloxicam to canine SF and plasma at comparable levels to oral Metacam® suspension and meloxicam was stable in delivra™ for up to 2 months. However, initial work with TDM did not demonstrate significant anti-inflammatory or analgesic effects in a rat model of inflammation.
Date: 2014-08
Terms of Use: All items in the Atrium are protected by copyright with all rights reserved unless otherwise indicated.

Files in this item

Files Size Format View
Kumagai_Miyuki_201408_MSc.pdf 42.79Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record